Subsequently, the indication was extended to include its use as adjuvant therapy for 3 years following surgical resection of KIT-positive GIST, at a starting dose of 400 mg/day (DeMatteo et al., 2009; Novartis Pharmaceuticals, 2012). Here, KIT is linked to gastrointestinal stromal tumor.